Stephen
Bloch,
M.D.
Chairman
Dr. Block has helped start and finance leading healthcare companies as a General Partner at Canaan Partners for more than 23 years. In addition to Canaan, he is currently CEO of EvolveImmune Therapeutics, a leader in next generation immune-oncology therapeutics and CEO of Allyx Therapeutics, whose lead program will enter phase 2 testing in Alzheimer’s and Parkinson’s patients in 2025. Steve was BioCT’s Entrepreneur of the Year in 2023. Steve has served on the boards of companies in biopharma, digital health, medical devices and diagnostics, often as board chairman. Before joining Canaan in 2002, Steve helped create and manage multiple start-ups, including RMS, one of the first radiology benefits companies where he was CEO for six years. Previously, Steve was a strategic pharmaceutical consultant for Arthur D. Little and an Ewing Marion Kauffman Fellow. Steve is currently a member of Dartmouth-Geisel Medical School’s Board of Advisors. Steve obtained his AB from Dartmouth College, a MA in the history of science from Harvard, and his medical degree from the University of Rochester. Steve completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).
Chairman of the Board
Dr. Block has helped start and finance leading healthcare companies as a General Partner at Canaan Partners for more than 23 years. In addition to Canaan, he is currently CEO of EvolveImmune Therapeutics, a leader in next generation immune-oncology therapeutics and CEO of Allyx Therapeutics, whose lead program will enter phase 2 testing in Alzheimer’s and Parkinson’s patients in 2025. Steve was BioCT’s Entrepreneur of the Year in 2023. Steve has served on the boards of companies in biopharma, digital health, medical devices and diagnostics, often as board chairman. Before joining Canaan in 2002, Steve helped create and manage multiple start-ups, including RMS, one of the first radiology benefits companies where he was CEO for six years. Previously, Steve was a strategic pharmaceutical consultant for Arthur D. Little and an Ewing Marion Kauffman Fellow. Steve is currently a member of Dartmouth-Geisel Medical School’s Board of Advisors. Steve obtained his AB from Dartmouth College, a MA in the history of science from Harvard, and his medical degree from the University of Rochester. Steve completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).